Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MDUFMA corrections delayed, Bush signs contact lens law

This article was originally published in The Gray Sheet

Executive Summary

Passage of technical corrections to the Medical Device User Fee & Modernization Act is postponed at least until January as Congress closes for holiday recess. Following Senate approval, the bill (S 1881) was referred to the House Committee on Energy & Commerce Dec. 8. Separately, legislation mandating passive prescription verification for contact lenses beats adjournment deadline, and is signed by the President Dec. 6 (1"The Gray Sheet" Nov. 24, 2003, p. 16)...

You may also be interested in...



Ophthalmic Devices In Brief

Noncorrective contact lenses: House-passed bill (HR 2218) would provide for the regulation of all contact lenses - including noncorrective plano products - as medical devices. Introduced by John Boozman (R-Ark.) in May, the legislation passed the House Nov. 19 in a voice vote, following referral to the Energy & Commerce Committee before Congress' August recess (1"The Gray Sheet" Aug. 25, 2003, p. 8). A Senate companion (S 1747) sponsored by Sen. Mike DeWine (R-Ohio) was referred to the HELP Committee in October...

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel